drugset / Trial / NCT00551096
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
Zactima will be used in this study to determine the highest dose that can be given safely as well as the side effects of Zactima when in combination with two FDA approved drugs; gemcitabine and capecitabine. This combination will be given to patients with advanced solid tumors. Once the highest dose of the combination has been determined, additional patients with biliary cancers (cholangiocarcinomas and gallbladder cancer) and locally advanced or metastatic pancreatic cancer will be treated at the highest determined dose for further studies.
Timeline
- Start
- 2007-10
- Primary completion
- 2013-05
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vandetanib | Small molecule | 200 mg | Oral |
| Subject | Vandetanib | Small molecule | 300 mg | Oral |
| Background | Capecitabine | Small molecule | 1660 mg/m2 | Oral |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |